JP2022536728A5 - - Google Patents
Info
- Publication number
- JP2022536728A5 JP2022536728A5 JP2021573593A JP2021573593A JP2022536728A5 JP 2022536728 A5 JP2022536728 A5 JP 2022536728A5 JP 2021573593 A JP2021573593 A JP 2021573593A JP 2021573593 A JP2021573593 A JP 2021573593A JP 2022536728 A5 JP2022536728 A5 JP 2022536728A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- benzyl
- oxy
- butanoic acid
- fluorophenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860571P | 2019-06-12 | 2019-06-12 | |
| US62/860,571 | 2019-06-12 | ||
| PCT/US2020/037527 WO2020252336A1 (en) | 2019-06-12 | 2020-06-12 | Dibenzylamines as amino acid transport inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536728A JP2022536728A (ja) | 2022-08-18 |
| JP2022536728A5 true JP2022536728A5 (enExample) | 2023-06-20 |
Family
ID=71409525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573593A Pending JP2022536728A (ja) | 2019-06-12 | 2020-06-12 | アミノ酸輸送阻害剤としてのジベンジルアミン類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220265590A1 (enExample) |
| EP (1) | EP3983377A1 (enExample) |
| JP (1) | JP2022536728A (enExample) |
| CN (1) | CN114269715A (enExample) |
| AU (1) | AU2020291936A1 (enExample) |
| CA (1) | CA3141414A1 (enExample) |
| WO (1) | WO2020252336A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20240174658A1 (en) * | 2021-03-01 | 2024-05-30 | Vanderbilt University | Heteroaromatic Inhibitors of Cancer Metabolism |
| KR102635329B1 (ko) * | 2021-07-21 | 2024-02-13 | 경북대학교 산학협력단 | 혈관평활근세포의 증식 또는 이동 억제 효과를 갖는 화합물을 유효성분으로 포함하는 혈관평활근세포 이상 증식성 질환의 예방 또는 치료용 약학적 조성물 |
| CN117466761B (zh) * | 2022-07-21 | 2026-04-28 | 中国药科大学 | 谷氨酰胺转运抑制剂、药物组合物和应用 |
| CN116410152B (zh) * | 2023-04-13 | 2023-11-03 | 江苏征瑞医药科技有限公司 | 一种抑制asct2的小分子化合物、其衍生物及其应用 |
| CN117550997B (zh) * | 2023-11-09 | 2025-12-19 | 中国药科大学 | 一种lat1抑制剂及其制法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| EP0084796B1 (en) | 1982-01-22 | 1990-05-02 | Cetus Corporation | Hla typing method and cdna probes used therein |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP2015525781A (ja) | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 免疫応答の調節 |
| RS60538B1 (sr) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
| IL321966A (en) | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| WO2015132672A2 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| WO2018107173A1 (en) * | 2016-12-09 | 2018-06-14 | Vanderbilt University | Glutamine transport inhibitors and methods for treating cancer |
-
2020
- 2020-06-12 WO PCT/US2020/037527 patent/WO2020252336A1/en not_active Ceased
- 2020-06-12 AU AU2020291936A patent/AU2020291936A1/en not_active Abandoned
- 2020-06-12 US US17/618,838 patent/US20220265590A1/en active Pending
- 2020-06-12 CA CA3141414A patent/CA3141414A1/en active Pending
- 2020-06-12 CN CN202080056932.1A patent/CN114269715A/zh active Pending
- 2020-06-12 JP JP2021573593A patent/JP2022536728A/ja active Pending
- 2020-06-12 EP EP20735757.5A patent/EP3983377A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| JP6779793B2 (ja) | リンパ腫を治療するためのｅｚｈ２阻害剤 | |
| US20230210852A1 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| JP6769982B2 (ja) | Ｒａｓ変異と関連するがんの治療方法 | |
| JP7539175B2 (ja) | 医薬組成物 | |
| JP5646327B2 (ja) | 癌および血管新生の治療のための、化学療法剤と組み合わせたベンゾキノン誘導体ｅ３３３０ | |
| CN112585136B (zh) | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 | |
| JP2019218375A5 (enExample) | ||
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| CN1798544A (zh) | 喜树碱和氟嘧啶的组合物 | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2024109766A (ja) | 医薬組成物 | |
| JP2004505105A5 (enExample) | ||
| USRE50319E1 (en) | Compounds and methods for treating cancer | |
| JP2013540114A5 (enExample) | ||
| CN1531435A (zh) | 抑制血管生成的方法 | |
| JP2018525414A (ja) | 癌を処置するための方法 | |
| JP2019518048A (ja) | がんの予防および／または治療のための化合物、組成物および方法 | |
| JP2026040489A (ja) | 骨髄増殖性新生物の治療のためのリシン特異的ヒストンデメチラーゼ阻害剤 | |
| JP2004520263A (ja) | 双極性障害における躁病を治療するためのバルプロ酸および２−バルプロエン酸アミド誘導体の使用 | |
| CN105246483A (zh) | 用于γ-谷氨酰循环调节的方法和组合物 | |
| EP4725489A2 (en) | Treatment of canine cancers | |
| JP2016512501A5 (enExample) | ||
| AU2023235307A1 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer | |
| JP2025513929A (ja) | がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ |